Tobacco, alcohol and illicit drugs during pregnancy and risk of neuroblastoma: systematic review. Issue 5 (21st November 2017)

• Record Type: Journal Article
• Authors: Müller-Schulte, Eloise; Kurlemann, Gerhard; Harder, Anja
• Is Part Of: Archives of disease in childhood. Volume 103:Issue 5(2018)
• Page Start: F467
• Page End: F473
• Publication Date: 2017-11-21
• Subjects: oncology -- epidemiology; Infants -- Diseases -- Periodicals; Newborn infants -- Diseases -- Periodicals; Fetus -- Diseases -- Periodicals; 618.920105
• DOI: 10.1136/archdischild-2017-313615
• Languages: English
• ISSNs: 1359-2998

Abstract

Abstract : Objective: To determine whether prenatal and perinatal maternal consumption of alcohol, tobacco and/or illicit drugs is associated with risk of neuroblastoma. Data sources: Medline and Embase (both from inception to February 2017), and reference lists of included studies. Study selection: To be eligible, a study had to be an original report including data on intake of alcohol, tobacco smoking and/or consumption of illicit drugs during pregnancy and risk of neuroblastoma in the child. Data extraction: From eligible studies, data study characteristics as well as effect measures and confounders were extracted. We assessed unadjusted and confounder-adjusted estimates, performed risk of bias analysis, constructed random-effects models and assessed heterogeneity. Results: We identified 14 case–control studies (1987–2016) involving a total of 3114 children with neuroblastoma. Meta-analysis of unadjusted estimates showed an association between alcohol (OR 1.26; 95% CI 1.07 to 1.49), tobacco (OR 1.22; 95% CI 1.04 to 1.44) and illicit drug consumption during pregnancy and risk of neuroblastoma during childhood, with illicit drug consumption showing the strongest association (OR 3.26; 95% CI 1.36 to 7.86). However, adjusted estimates were highly heterogeneous. Limitations: All studies were at high risk of bias. Conclusions: Smoking, alcohol or illicit drugs during pregnancy might play a role in the development of neuroblastoma. However, well-designed studies are needed to assess whether these exposures are causal and whether time period during pregnancy, dose or co-consumption of substances is critical. Trial registration number: Registration number CRD42016036165.